Skip to content
Permalink
main
Switch branches/tags

web-hack-mirror/mirror/1999/12/18/www.curearthritis.org/cureart1.htm

Go to file
 
 
Cannot retrieve contributors at this time
657 lines (649 sloc) 42.9 KB
Raw Blame
Open in GitHub Desktop
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
<title>CureARTHRITIS</title>
</head>
<body bgcolor="#FFFFFF">
<div align="center"><center>
<table border="0" cellspacing="0" width="100%">
<tr>
<td width="12%" valign="bottom"><p align="left"><a href="index.htm"><img
src="IMAGES/ANR_logo-sm.gif" border="0" width="80" height="83"></td>
<td width="18%" valign="bottom"></a><font color="#400080">Press logo to return to main
menu.</font></td>
<td width="40%"><img src="IMAGES/CA_banner.gif" alt="Cure Arthritis Online" width="373"
height="152" border="0"></td>
<td width="18%" valign="bottom"><p align="right"><font color="#400080">Press here to see
back issues of </font><font color="#FF0000">Cure</font><font color="#400080">Arthritis.</font><a
href="index.htm"></td>
<td width="12%" valign="bottom"></a><a href="curearth.htm"><img src="IMAGES/CA_back.gif"
border="0" width="80" height="83"></a></td>
</tr>
</table>
</center></div>
<hr color="#FF0000">
<div align="center"><center>
<table border="2" width="100%" cellpadding="4">
<tr>
<td width="33%"
style="background-color: rgb(255,215,235); padding-left: 4; padding-right: 4"><p
align="center"><a href="#Article1"><font face="Times New Roman" color="#400080"><strong>Which
renowned scientists joined ANRF's Scientific Advisory Board? To find out, click here.</strong></font></a></td>
<td width="33%" style="padding-left: 4; padding-right: 4" valign="middle" align="center"><img
src="IMAGES/Inside.gif" alt="Inside this Issue" width="158" height="132" border="0"></td>
<td width="34%"
style="background-color: rgb(255,215,235); padding-left: 4; padding-right: 4"><p
align="center"><a href="#Article6"><font face="Times New Roman" color="#400080"><strong>Can
golfing or doing the &quot;chicken dance&quot; cure arthritis? Click here for the details.</strong></font></a></td>
</tr>
<tr>
<td width="33%"
style="background-color: rgb(255,215,235); padding-left: 4; padding-right: 4" rowspan="2"><p
align="center"><a href="#Article2"><font face="Times New Roman" color="#400080"><strong>1997-98
in review.<br>
For the Annual Report, click here.</strong></font></a></td>
<td width="33%"
style="background-color: rgb(255,215,235); padding-left: 4; padding-right: 4"><p
align="center"><a href="names.htm"><font face="Times New Roman" color="#400080"><strong>Find
your name<br>
on our supporters list.</strong></font></a></td>
<td width="34%"
style="background-color: rgb(255,215,235); padding-left: 4; padding-right: 4" rowspan="2"><p
align="center"><a href="#Article3"><strong><font face="Times New Roman" color="#400080">Click
here to see the ANRF<br>
grant recipients for 1998-99.</font></strong></a></td>
</tr>
<tr>
<td width="33%"
style="background-color: rgb(255,215,235); padding-left: 4; padding-right: 4"><font
face="Times New Roman" color="#400080"><strong><p align="center"><a href="#Article4"><span
style="color: rgb(64,0,128)">Discover new hope<br>
for arthritis pain management.<br>
</span></a></strong></font></td>
</tr>
</table>
</center></div><div align="center"><center>
<table border="0" width="100%" cellspacing="0" style="margin-top: 12; padding-top: 12">
<tr>
<td width="33%"></td>
<td width="11%"><font face="Times New Roman" color="#400080"><strong><img
src="images/ANR_logo-sm.gif" alt="ANRF logo" border="0" width="80" height="83"></strong></font></td>
<td width="22%" valign="top"><font face="Times New Roman" color="#400080"><strong>CureArthritis
Online </strong>is a periodic publication of the Arthritis National Research Foundation.</font></td>
<td width="34%"></td>
</tr>
<tr>
<td width="100%" colspan="4"><font face="Times New Roman" color="#400080"><strong><p
align="center"></strong>200 Oceangate, Suite 400, Long Beach, CA 90802 </font><font
face="Wingdings" size="1" color="#FF0000">l</font><font face="Times New Roman"
color="#400080"> 800-588-CURE, fax: 562-983-1410, e-mail: <a
href="mailto:anrf@ix.ntcom.com">anrf@ix.ntcom.com</a></font></p>
<p align="center">&nbsp;</td>
</tr>
</table>
</center></div><div align="center"><center>
<table border="0" cellspacing="0" width="100%" cellpadding="0">
<tr>
<td width="100%" background="IMAGES/ANRFtile.gif" height="20">&nbsp;<div align="center"><center><table
border="0" cellspacing="0" width="684" height="344">
<tr>
<td width="682" colspan="3" valign="bottom" style="margin-top: 0; padding-top: 0"><a
name="Article1"><font color="#400080"><big><big><big>Renowned Scientists Agree to Serve</big></big></big><br>
<big><big><big>on ANRF Scientific Advisory Board</big></big></big></font></a></td>
</tr>
<tr>
<td width="565" valign="top" style="padding-left: 10; padding-right: 10" colspan="2"><font
face="Times New Roman" size="3">The Arthritis National Research Foundation&#146;s mission
is to provide grant funds to young investigators studying the causes of and new treatments
for arthritis. ANRF has called upon top researchers and scientists to become members of a
newly formed Scientific Advisory Board. The doctors of the Scientific Advisory Board are
respected nationwide for their individual expertise in the field of arthritis and
immunological research.</font><p><font face="Times New Roman" size="3">The individual
members of ANRF's Scientific Advisory Board have committed their expertise to furthering
the principles and goals of our organization on a regular basis. These scientists believe
that ANRF plays a critical role in the field of rheumatic disease research: the Foundation
funds young investigators, often giving them a &#147;jump start&#148; on their research
careers. The Advisory Board members will be reviewing the grant proposals received by ANRF
each year and recommend grant recipients, as well as providing advice to the Board of
Directors on the trends in research and clinical treatments. The Scientific Advisory Board
will be instrumental in implementing the organization's goal of funding more research
projects each year. Their collective presence takes ANRF to a higher level of respect and
prestige in the world of medical research.</font></p>
<p><font face="Times New Roman" size="4" color="#400080">Meet the Scientific Advisory
Board</font></p>
<p><font face="Times New Roman" size="3"><font color="#400080"><strong>John H. Vaughan,
M.D., University of California, San Diego</strong></font><br>
Dr. Vaughan is a past president of the American College of Rheumatology and has been
studying the pathogenesis of rheumatoid arthritis throughout his career. A graduate of
Harvard Medical School, Dr. Vaughan has directed the Immunology and Infectious Diseases
Unit of the University of Rochester Medical School (1963-70), chaired the Clinical
Research Department and the Clinical Immunology Department at Scripps Research Institute
(1970-1989), and has been a Professor of Medicine at the University of California, San
Diego since 1990.</font></p>
<p><font face="Times New Roman" size="3">Dr. Vaughan's career has been in teaching and
research in the areas of allergy and the autoimmune diseases, such as rheumatoid
arthritis. His major research contributions have been in elucidating the nature and
significance of autoantibodies, early studies on the nature of cellular immunity, and more
recent explorations of the probable contribution of virus infection in the autoimmune
diseases. Dr. Vaughan is a former grant recipient of ANRF.</font></p>
<p><font face="Times New Roman" size="3"><font color="#400080"><strong>James Klinenberg,
M.D., Cedars-Sinai Medical Center, Los Angeles</strong></font><br>
Dr. Klinenberg has served as president of the American College of Rheumatology and is
currently Professor of Medicine and Assistant Dean of the UCLA School of Medicine. He
earned his M.D. from the George Washington School of Medicine in 1959; his undergraduate
and M.A. work was completed at Johns Hopkins University.</font></p>
<p><font face="Times New Roman" size="3">In addition to the American College of
Rheumatology presidency, Dr. Klinenberg has held numerous positions of leadership in
education, research and professional organizations, including the Association of American
Medical Colleges, American College of Physicians, California Biomedical Research
Association, local and national Arthritis Foundation, and Cedars-Sinai Medical Center. His
research throughout most of his career has focused on the causes and mechanisms of
rheumatic diseases, with an emphasis on the autoimmune diseases of lupus and rheumatoid
arthritis.</font></p>
<p><font face="Times New Roman" size="3"><font color="#400080"><strong>Hugh McDevitt,
M.D., Stanford University Medical Center</strong></font><br>
Dr. McDevitt is known world-wide for his contributions to the field of arthritis research.
He is currently a professor of Mediciine, and Microbiology &amp; Immunology at the
Stanford University School of Medicine. A 1955 graduate of Harvard University Medical
School, Dr. McDevitt has received honors and awards for his research- related work from
academic and professional organizations ranging from the National Institutes of Health to
the National Cancer Institute to the American College of Rheumatology, and more.</font></p>
<p><font face="Times New Roman" size="3">He currently serves on the Advisory Committee to
the Director of the National Institutes of Health, as well as on the editorial boards of
the publications, Molecular Medicine and The Journal of Clinical Immunology,
Immunopathology, Immunogenetics. At Stanford University, Dr. McDevitt has been the head of
the Immunology Department, the director of the Clinical Immunology Lab, and the Chairman
of the Department of Microbiology and Immunology.</font></p>
<p><font face="Times New Roman" size="3"><font color="#400080"><strong>Grete Sonderstrup,
M.D., Stanford University Medical Center</strong></font><br>
Dr. Sonderstrup is an Assistant Professor of Medicine in the Division of Immunology and
Rheumatology at Stanford University Medical Center. She earned her M.D. from the
University of Copenhagen in 1974, coming to the U.S. in 1986 to continue her research in
immunology. Dr. Sonderstrup is a speaker in high demand, having been invited to
universities and conferences all over the world to discuss her research work in rheumatoid
arthritis. ANRF provided funding for Dr. Sonderstrup¹s work in 1993.</font></p>
<p><font face="Times New Roman" size="3"><font color="#400080"><strong>Eng M. Tan, M.D.,
Scripps Research Institute</strong></font><br>
Dr. Tan is Professor and Head of the Autoimmune Disease Center at the Scripps Research
Institute in La Jolla, CA. He earned his M.D. degree from Johns Hopkins University in
1956. After his medical internship and residency, Dr. Tan began his post-doctoral research
at Case Western Reserve University in Cleveland, then Rockefeller University in New York.
He joined the Scripps Clinic and Research Foundation in 1967, and was head of the
Department of Allergy &amp; Immunology from 1970 to 1977. Since 1982, Dr. Tan has been
head of the W.M. Keck Autoimmune Disease Center, where his work has centered on studies of
autoantigens and autoantibodies in systemic rheumatic diseases and cancer.</font></p>
<p><font face="Times New Roman" size="3">Dr. Tan is a past president of the American
Rheumatism Association, and has served on numerous advisory boards and research committees
for the National Institutes of Health and various national scientific and medical
organizations. In recognition of his achievement in this research field, Dr. Tan has
received awards from organizations worldwide.</font></p>
<p><font face="Times New Roman" size="3"><font color="#400080"><strong>Carl F. Ware,
Ph.D., La Jolla Institute for Allergy and Immunology</strong></font><br>
Dr. Ware received his Ph.D. from the University of California, Irvine in Molecular Biology
and Biochemistry in 1979. He did his postdoctoral research at the University of Texas,
Health Science Center, San Antonio, the Dana-Farber Cancer Institute in Boston, and the
Department of Microbiology and Molecular Genetics at Harvard Medical School. Dr. Ware
joined the La Jolla Institute for Allergy and Immunology (LIAI) in 1996 as Head and Member
of the Division of Molecular Immunology and is also currently Adjunct Professor of Biology
at the University of California, San Diego.</font></p>
<p><font face="Times New Roman" size="3">A major goal of LIAI's projects in Molecular
Immunology is to understand how lymphotoxins and TNF, and newly discovered proteins induce
cell death and growth, and to research the underlying factors that regulate the human
immune system. Dr. Ware is considered an expert in the field of molecular immunology. </font></td>
<td width="115" style="padding-left: 10; padding-right: 10" valign="top"></td>
</tr>
<tr>
<td width="565" height="29" colspan="2"><font face="Arial Black" color="#FF0000"><em>Annual
Report</em></font><br>
<a name="Article2"><big><big><font color="#400080"><big>ANRF Makes New Strides in
1998-1999 </big></font></big></big></a></td>
</tr>
<tr>
<td width="565" valign="top"
style="padding-left: 10; padding-right: 10; padding-bottom: 10" colspan="2"><font
face="Times New Roman" size="3">This has been an exciting year for the Arthritis National
Research Foundation. The Board of Directors is committed to increasing our annual income
so that we are able to fund a greater number of promising young investigator&#146;s
projects. In each of the last three years, we have met this goal.</font><p><font
face="Times New Roman" size="3">The 1998-1999 grant recipients represent the best and
brightest young scientists seeking to understand the nature and cause of arthritis. Most
of these studies center around the autoimmune diseases of rheumatoid arthritis (RA) and
Systemic Lupus Erythematosus (SLE or lupus). In autoimmune disease, the patient's immune
system is attacking and destroying self-tissues. By studying the causes of these
diseases, scientists will be able to devise new therapies to fight them at the cell level.
In fact, we are beginning to see disease-modifying therapies, not just anti-inflammatory
drugs to help control pain.</font></p>
<p><font face="Times New Roman" size="3">One such new therapy for rheumatoid arthritis is
a drug called &#147;Enbrel,&#148; which recently received FDA approval. The drug has been
developed by the Immunex Corporation and has been tested in clinical trials across the
country. Enbrel is a protein-based drug comprising only human amino acid sequences; in
other words, substances already produced in the human body. The drug inhibits TNF (tumor
necrosis factor) biological activity. In RA, excess TNF combines with cell-surface TNF
receptors to produce a cascade of damaging and inflammatory effects on joints. Enbrel is
thought to interfere specifically with the inflammatory process in RA, which is believed
to be driven by TNF. (See page 5 for more information on Enbrel.)</font></p>
<p><font face="Times New Roman" size="3">ANRF is proud of the research it funded in the
1970's and 1980's which led to the original discovery of TNF, the target of these new
therapies.</font></p>
<p><font face="Times New Roman" size="3">The Scientific Advisory Board adds a new
dimension to the scope and prestige of the Arthritis National Research Foundation. The
collective expertise of these renowned scientists and physicians will help the Foundation
expand its influence into the next century. The Board of Directors is indeed grateful for
their commitment to the Foundation's goals: helping young investigators study the basic
science of rheumatic diseases in an effort to develop new therapies and, ultimately, a
cure.</font></p>
<p><font face="Times New Roman" size="3">Thank you for your generous support of arthritis
research as we work together toward improving the quality of life for those in pain.</font></p>
<p align="center"><img src="Images/gale_sig.gif" width="120" height="46"
alt="gale_sig.gif (1087 bytes)"><font face="Times New Roman" size="3"><br>
Gale A. Granger,Ph.D.<br>
President </font></td>
<td valign="top" style="padding-left: 10; padding-right: 10; padding-bottom: 10"
width="115"></td>
</tr>
<tr>
<td width="565" height="14" bgcolor="#FFD0E8" colspan="2"><p align="center"><font
face="Times New Roman" color="#400080"><big><strong>Financial Report<br>
</strong></big></font><font face="Times New Roman" size="3" color="#400080"><em>Audited
Statement of Public Support<br>
Fiscal Year Ending March 31, 1998</em></font></td>
<td width="115" height="14"></td>
</tr>
<tr>
<td width="565" height="14" bgcolor="#FFD0E8" colspan="2"><div align="center"><center><table
border="1" cellpadding="4" cellspacing="1" width="100%" bordercolor="#FF00FF"
bordercolorlight="#FFFFFF" bordercolordark="#FF0000">
<tr>
<td width="100%" colspan="4"><p align="center"><font size="3"><strong>Revenues and
Expenses 1997-98</strong></font></td>
</tr>
<tr>
<td width="70%" colspan="2"><font size="3" color="#400080"><strong>Public Support and
Revenue</strong></font></td>
<td width="15%"><p align="center"><strong>1998</strong></td>
<td width="15%"><p align="center"><strong>1997</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Contributions</strong></td>
<td width="15%" align="right"><strong>$112,407</strong></td>
<td width="15%" align="right"><strong>$33,639</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Investment Income</strong></td>
<td width="15%" align="right"><strong>138,134</strong></td>
<td width="15%" align="right"><strong>77,696</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Other Income</strong></td>
<td width="15%" align="right"><strong>593</strong></td>
<td width="15%" align="right"><strong>275</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Unrealized Gain on Investment</strong></td>
<td width="15%" align="right"><strong>258,370</strong></td>
<td width="15%" align="right"><strong>35,887</strong></td>
</tr>
<tr>
<td width="70%" colspan="2"><font color="#400080"><strong>Total Support and Revenue</strong></font></td>
<td width="15%" align="right"><font color="#400080"><strong>$509,504</strong></font></td>
<td width="15%" align="right"><font color="#400080"><strong>$147,497</strong></font></td>
</tr>
<tr>
<td width="70%" colspan="2"><strong><font color="#400080">Expenses<br>
</font>Program Services</strong></td>
<td width="15%">&nbsp;</td>
<td width="15%">&nbsp;</td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Research</strong></td>
<td width="15%" align="right"><strong>$132,006</strong></td>
<td width="15%" align="right"><strong>$118,135</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Education</strong></td>
<td width="15%" align="right"><strong>44,600</strong></td>
<td width="15%" align="right"><strong>24,725</strong></td>
</tr>
<tr>
<td width="70%" colspan="2"><strong>Total Program Services</strong></td>
<td width="15%" align="right"><strong>176,606</strong></td>
<td width="15%" align="right"><strong>142,860</strong></td>
</tr>
<tr>
<td width="70%" colspan="2"><strong>Supporting Services</strong></td>
<td width="15%" align="right">&nbsp;</td>
<td width="15%" align="right">&nbsp;</td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Mangement and General</strong></td>
<td width="15%" align="right"><strong>$27,316</strong></td>
<td width="15%" align="right"><strong>$100,000</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Fund Development</strong></td>
<td width="15%" align="right"><strong>10,534</strong></td>
<td width="15%" align="right"><strong>16,006</strong></td>
</tr>
<tr>
<td width="70%" colspan="2"><strong>Total Supporting Services</strong></td>
<td width="15%" align="right"><strong>37,850</strong></td>
<td width="15%" align="right"><strong>55,521</strong></td>
</tr>
<tr>
<td width="70%" colspan="2"><font color="#400080"><strong>Total Expenses<br>
<em>Change in Unrestricted Net Assets</em></strong></font></td>
<td width="15%" align="right"><font color="#400080"><strong>$214,456<br>
<em>$295,048</em></strong></font></td>
<td width="15%" align="right"><font color="#400080"><strong>$198,381<br>
<em>($50,884)</em></strong></font></td>
</tr>
<tr>
<td width="100%" colspan="4"><p align="center"><font face="Times New Roman"
color="#400080"><big><strong>Statement of Financial Position 1997-98</strong></big></font></td>
</tr>
<tr>
<td width="70%" colspan="2"><font color="#400080"><strong>Assets</strong></font></td>
<td width="15%"><p align="center"><strong>1998</strong></td>
<td width="15%"><p align="center"><strong>1997</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Cash and cash equivalent</strong></td>
<td width="15%" align="right"><strong>$102,736</strong></td>
<td width="15%" align="right"><strong>$56,566</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Note receivable</strong></td>
<td width="15%" align="right"><strong>0</strong></td>
<td width="15%" align="right"><strong>13,989</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Accrued interest and dividends</strong></td>
<td width="15%" align="right"><strong>4,313</strong></td>
<td width="15%" align="right"><strong>16,006</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Prepaid expenses</strong></td>
<td width="15%" align="right"><strong>1,935</strong></td>
<td width="15%" align="right"><strong>2,696</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Investments</strong></td>
<td width="15%" align="right"><strong>1,680,158</strong></td>
<td width="15%" align="right"><strong>1,403,812</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Other investments</strong></td>
<td width="15%" align="right"><strong>4,301</strong></td>
<td width="15%" align="right"><strong>4,301</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Equipment, net</strong></td>
<td width="15%" align="right"><strong>3,598</strong></td>
<td width="15%" align="right"><strong>4,797</strong></td>
</tr>
<tr>
<td width="70%" colspan="2"><font color="#400080"><strong>Total Assets</strong></font></td>
<td width="15%" align="right"><font color="#400080"><strong>$1,797,041</strong></font></td>
<td width="15%" align="right"><font color="#400080"><strong>$1,502,167</strong></font></td>
</tr>
<tr>
<td width="70%" colspan="2"><font color="#400080"><strong><em>Liabilities and Net Assets</em><br>
Liabilities</strong></font></td>
<td width="15%">&nbsp;</td>
<td width="15%">&nbsp;</td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Accounts Payable</strong></td>
<td width="15%" align="right"><strong>$2,987</strong></td>
<td width="15%" align="right"><strong>$3,161</strong></td>
</tr>
<tr>
<td width="10%">&nbsp;</td>
<td width="60%"><strong>Unrestricted Net Assets</strong></td>
<td width="15%" align="right"><strong>1,794,054</strong></td>
<td width="15%" align="right"><strong>1,499,006</strong></td>
</tr>
<tr>
<td width="70%" colspan="2"><font color="#400080"><strong>Total Liabilities and Net Assets</strong></font></td>
<td width="15%" align="right"><font color="#400080"><strong>$1,797,041</strong></font></td>
<td width="15%" align="right"><font color="#400080"><strong>$1,502,167</strong></font></td>
</tr>
</table>
</center></div></td>
<td width="115" height="14"></td>
</tr>
<tr>
<td width="682" height="38" colspan="3"><font color="#400080"><br>
</font><font face="Arial Black" color="#FF0000"><em>Sowing the Seeds of Research</em></font><br>
<a name="Article3"><font color="#400080"><big><big><big>1998-1999 ANRF Grants:</big></big></big><br>
<font face="Times New Roman" size="5">Rheumatoid Arthritis,</font></font><font
face="Times New Roman" size="5" color="#400080"> Lupus Disease Pathways Studied</font></a></td>
</tr>
<tr>
<td width="565" valign="top"
style="padding-left: 10; padding-right: 10; padding-bottom: 10" colspan="2"><font
face="Times New Roman" size="3">The Arthritis National Research Foundation has funded four
scientific studies investigating the disease pathways that lead to the debilitating
autoimmune diseases, rheumatoid arthritis, lupus (SLE) and scleroderma. The studies range
from pinpointing the genetic make-up of cells susceptible to Rheumatoid Arthritis to
understanding the human immune system¹s malfunctioning in Systemic Lupus Erythematosus
(SLE or Lupus).</font><p><font face="Times New Roman" size="3">&#147;Understanding the
disease pathway is the first step toward determining the cause of the disease and,
ultimately develop new therapies,&#148; said Gale A. Granger, Ph.D., Arthritis National
Research Foundation president and Professor of Immunology at the University of California,
Irvine. &#147;The four investigators receiving grants from ANRF this year exemplify the
Foundation¹s dedication to studying why and how the body reacts as it does in the
pathogenesis of these autoimmune diseases.&#148;</font></p>
<p><font face="Times New Roman" size="3">A normally functioning immune system enables us
to recover from infections by releasing antibodies to attack foreign, unwanted substances.
In Rheumatoid Arthritis (RA) and Lupus, which are autoimmune diseases, this highly
efficient immune system has made a mistake and is attacking &#147;self tissues.&#148;
While not the most prevalent form of arthritis (osteoarthritis impacts over 17 million
Americans), RA and Lupus are the most painful and crippling rheumatic diseases, affecting
nearly eight million Americans.</font></p>
<p><font face="Times New Roman" size="3">The investigators awarded grants for the 1998-99
grant cycle are:</font></p>
<p><font face="Times New Roman" size="3"><strong>Susan Kovats, Ph.D., </strong>Beckman
Research Institute, City of Hope<strong><br>
Elizabeth Mellins, M.D., </strong>Stanford University Medical Center<strong><br>
Rebecca Tuetken, M.D.,</strong> Ph.D., University of Iowa<strong><br>
Paul Utz, M.D., </strong>Harvard Medical School, Brigham &amp; Women&#146;s Hospital</font></p>
<p><font face="Times New Roman" size="3"><em>Susan Kovats, Ph.D</em>., of the Beckman
Research Institute at City of Hope in Duarte, California, received a $35,000 grant to
study the nature of self-antigens (substances released by the body, as opposed to foreign
substances, to stimulate production of antibodies) in Rheumatoid Arthritis. Her
investigation will focus on whether tissue damage or infection confuse the recognition
mechanism of the immune system, thereby attacking self-tissues as if they were foreign.
&#147;Insights to these self-antigens will aid the design of strategies for therapeutic
intervention in RA,&#148; said Dr. Kovats. Dr. Kovats received her Ph.D. from the
University of Wisconsin in 1991, and is currently an Assistant Research Scientist in the
Beckman Institute's Division of Immunology.</font></p>
<p><font face="Times New Roman" size="3"><em>Elizabeth Mellins, M.D</em>., at Stanford
University Medical Center, received $40,000 to test the hypothesis that RA susceptible
genes interact differently with key regulators in the RA disease pathway than do
non-susceptible genes. Specifically, she will investigate if inherited genetic alterations
in the recognition mechanism of the immune system are defective and cause the patient to
identify certain self-antigens as foreign. This novel approach may yield insight into RA
pathogenesis, providing fuel for new therapeutic strategies. Dr. Mellins is a practicing
pediatric rheumatologist and an innovator in the field of antigen presentation. She
received her M.D. from Harvard Medical School in 1978 and has taught both Pediatrics and
Rheumatology at the University of Washington, University of Pennsylvania and Stanford
University Medical Center.</font></p>
<p><font face="Times New Roman" size="3"><em>Rebecca Tuetken, M.D., Ph.D</em>., at the
University of Iowa, received $40,000 to study the mechanism of how the immune system
recognizes and reacts against foreign and self-DNA (genetic information). This will help
explain how certain patients with autoimmune diseases react against their own DNA.
&#147;My hope is that this study will provide both a more complete understanding of the
innate immune response to bacterial DNA and new insights in the pathogenesis of SLE,
possibly leading to new therapeutic approaches,&#148; said Dr. Tuetken. Currently a
post-doctoral fellow in Rheumatology at the University of Iowa Hospitals and Clinics, Dr.
Tuetken received her Ph.D. in Immunology and M.D. from the University of Chicago Pritzker
School of Medicine in 1989 and 1991, respectively.</font></p>
<p><font face="Times New Roman" size="3"><em>Paul Utz, M.D.</em>, at Brigham and Women's
Hospital (affiliated with Harvard Medical School) in Boston, received $40,000 to study
cell death's role in the development of autoimmune diseases such as lupus and
scleroderma. Dr. Utz's study will focus on the mechanism of how proteins released from
dying self-cells can be modified and how these modified proteins then stimulate the
patient's immune system. Once stimulated, the immune system will attack both dying and
living cells to cause autoimmune disease.</font></p>
<p><font face="Times New Roman" size="3">Successful completion of this project may greatly
advance the level of understanding of autoimmune disease mechanism. Dr. Utz is a
practicing rheumatologist and instructor at Brigham and Women's Hospital and Harvard
Medical School, who received his M.D. in 1991 from Stanford University School of Medicine.</font></p>
<p><em><font face="Times New Roman" size="3">Grants are awarded on an annual basis.
Proposals are peer-reviewed by the Medical Committee of the Board of Directors, as well as
by the Scientific Advisory Board, which comprises NIH-level expert scientists and
physicians in the field.</font></em></td>
<td width="115" valign="top"
style="padding-left: 10; padding-right: 10; padding-bottom: 10"></td>
</tr>
<tr>
<td width="682" height="38" colspan="3"><font face="Arial Black" color="#FF0000"><em>FDA
Approves New RA Treatment</em></font><br>
<a name="Article4"><font color="#400080"><big><big><big>New Hope for Arthritis Pain
Management</big></big></big></font></a></td>
</tr>
<tr>
<td width="565" valign="top"
style="padding-left: 10; padding-right: 10; padding-bottom: 10" colspan="2"><font
FACE="Arial" SIZE="2"><p align="left"></font><font face="Times New Roman" size="4"
color="#400080">Enbrel: The Long-Awaited TNF Inhibitor is Available<br>
</font><font face="Times New Roman" size="3">The FDA recently licensed a genetically
engineered protein that helps reduce symptoms of moderate to severe, active Rheumatoid
Arthritis (RA). RA affects over two million Americans and is an autoimmune disease in
which the body attacks self-tissues. The new treatment, called Enbrel, binds to the tumor
necrosis factor (TNF), a naturally occurring protein in the body, and inhibits its action.
TNF, which is believed to promote inflammation in the body, is found at elevated levels in
the fluid surrounding the affected joints of RA patients. This is the breakthrough
treatment referred to in the lead article of the last issue of CureArthritis. Now that the
FDA has approved this treatment, Enbrel injections will be available through your
physician.</font></p>
<p align="left"><font face="Times New Roman" size="3">Enbrel is an entirely new approach
to the management of RA. It is the first in a new class of drugs known as biologic
response modifiers, which specifically interrupt the inflammatory process. In clinical
studies, patients taking Enbrel had significantly reduced pain and the number of swollen
and tender joints. The drug is intended for those RA patients with moderate to severe RA
who have not been able to achieve relief with one or more disease modifying anti-rheumatic
drugs (DMARDs), such as methotrexate. It may also be used in combination with
methotrexate. Known side effects are: Mild to moderate injection site reactions. The
long-term effects, on the development or course of serious infection, malignancy and
autoimmune disease are unknown. Patients with a serious infection, or who are allergic to
Enbrel or any of its components should not take this medicine.</font></p>
<p align="left"><font face="Times New Roman" size="3">For more information, please consult
your physician, call the Immunex Corporation at 1-888-4ENBREL, or visit the
company-sponsored web site at&nbsp; <a href="http://www.Enbrelinfo.com">www.Enbrelinfo.com</a>.</font></p>
<p align="left"><font face="Times New Roman" size="4" color="#400080">Arava approved for
RA Treatment</font><br>
<font face="Times New Roman" size="3">In September, the FDA approved Arava (leflunomide)
as a new treatment for adult RA. This drug, which is taken in tablet form, inhibits at
least one enzyme in lymphocytes (cells of the immune system) and thereby interferes with
the RA disease process. In clinical trials, patients taking Arava showed significant
improvement in pain and swelling of joints and joint damage seemed to be retarded. Known
side effects are: Not recommended for patients with significant liver disease, children,
pregnant or nursing women. Patients may experience diarrhea or, rarely, liver problems,
hair loss, skin rash or hypertension.</font></p>
<p align="left"><font face="Times New Roman" size="4" color="#400080">Still in the FDA
pipeline<br>
Cox-2 Inhibitors: Pain Relief without Stomach Upset</font><font face="Times New Roman"
size="3"><br>
As many as 107,000 hospitalizations and 16,500 deaths occur each year in the United States
as a result of the use of non-steroidal anti-inflammatory drugs (NSAIDs), such as
ibuprofen, naproxen and aspirin. These drugs help pain management of arthritis, but
patients may develop moderate to severe gastrointestinal problems. One solution may be on
the way. A new class of drugs is being developed by Searle, and also by Merck &amp; Co.
These drugs are known as COX-2 inhibitors and are aimed at reducing the adverse effects on
the gastrointestinal system. The preliminary results are promising: the drugs seem to
target the COX-2 enzyme, produced primarily at the site of inflammation, while not
inhibiting the COX-1 enzyme, which is needed for proper digestive function. It is the
inhibition of COX-1, which is believed to be the cause of serious gastro-intestinal side
effects, such as ulcers, which have been associated with the use of NSAIDs.</font></p>
<p align="left"><font face="Times New Roman" size="3">The review of Searle&#146;s Celebrex
(celcoxib) is on the fast track at the FDA. The drug is still in the testing phase at this
time. You can visit Searle at their web site to obtain current information:
www.searlehealthnet.com. Vioxx is the Cox-2 inhibitor drug which Merck &amp; Co. is
currently testing.</font></p>
<p align="left"><font face="Times New Roman" size="4" color="#400080">Non-Drug Treatment
Alternative: Prosorba Column</font><font face="Times New Roman" size="3"><br>
The FDA Gastroenterology and Urology Device Advisory Panel recommended approval for the
treatment of moderate to severe rheumatoid arthritis of Prosorba Column. This treatment
has been used to treat Idiopathic Thrombocytopenic Purpura (ITP), an immune blood
disorder, since 1987. If final approval from the FDA is received, Prosorba Column would
also be used to treat RA.</font></p>
<p align="left"><font face="Times New Roman" size="3">Prosorba Column is a treatment
similar to kidney dialysis, in which blood is removed from the patient's arm and passed
through a machine that separates the blood cells from the plasma. The plasma is then
passed through the Prosorba Column, recombined with the blood cells and finally returned
to the patient through the other arm.</font></p>
<p align="left"><font face="Times New Roman" size="3">In clinical trials across the
country, patients who had failed with DMARDs (such as methotrexate) underwent 12 Prosorba
Column treatments. Nearly half of these patients showed significant reduction in swollen
and tender joint counts and the response was durable, some lasting as long as 75 weeks. </font></td>
<td width="115" valign="top"
style="padding-left: 10; padding-right: 10; padding-bottom: 10"></td>
</tr>
<tr>
<td width="682" height="38" colspan="3"><a name="Article6"><big><big><big><font
color="#400080">Special Events Give ANRF a Boost</font></big></big></big></a></td>
</tr>
<tr>
<td width="565" style="padding-left: 10; padding-right: 10; padding-bottom: 10"
valign="top" colspan="2"><font size="4" color="#400080">Oktoberfest Fundraiser</font><br>
This was ANRF's first year to participate with 12 other worthy charitable organizations in
an annual event sponsored by Alpine Village in Torrance, California. ANRF supporters were
given the opportunity to win valuable prizes; this year's grand prize was $5000. The
drawing took place opening day of the Alpine Village's Oktoberfest celebration and winners
did not need to be present. The Oktoberfest event included over 100 teams of two people
participating in a Stein Holding Contest- we're proud to say that an ANRF team finished
6th this year! Special thanks to the following sponsors for making this, our first year,
such a success:<p><strong>Molina Medical Centers</strong></p>
<p><strong>Reed, Conner &amp; Birdwell</strong></td>
<td width="115" style="padding-left: 10; padding-right: 10; padding-bottom: 10"
valign="top"></td>
</tr>
<tr>
<td width="283" style="padding-left: 10; padding-right: 10; padding-bottom: 10"
valign="top"><font size="4" color="#400080">Use It or Lose It Golf Classic</font><br>
The Arthritis national Research Foundation is proud to announce it&#146;s first annual
Golf Classic:<br>
<strong>May 24, 1999<br>
SeaCliff Country Club<br>
Huntington Beach, CA</strong><p>For more information or to receive an invitation, please
call <strong>800-588-CURE</strong>.<br>
Golf Chair: Jim Rose, Pharm.D.<br>
ANRF Board Member </td>
<td width="282" style="padding-left: 10; padding-right: 10; padding-bottom: 10"
valign="top"><p align="center"><a href="event.htm"><img src="Images/anrfgolf.gif"
width="200" height="213" alt="More information..." border="0"></a></td>
<td width="115" style="padding-left: 10; padding-right: 10; padding-bottom: 10"
valign="top"></td>
</tr>
</table>
</center></div><p align="center">&nbsp;</td>
</tr>
</table>
</center></div>
<p align="center"><b><font color="#0000FF">This page, and all the contents of this
Web site,<br>
are Copyright © 1999 by TouchVision,<br>
Seal Beach, California. All rights reserved.</font></b> <br>
<font size="2" face="ARIAL,HELVETICA"><b>Best experienced with<br>
<a href="http://www.microsoft.com/ie/ie.htm"><img src="ie_animated.gif"
alt="Microsoft Internet Explorer" border="0" vspace="7" width="88" height="31"></a> </b></font></p>
</body>
</html>